NASDAQ:SRNE
Delisted
Sorrento Therapeutics Stock News
$0.307
+0 (+0%)
At Close: Feb 23, 2023
Evogene (EVGN) Reports Q1 Loss, Lags Revenue Estimates
12:25pm, Thursday, 26'th May 2022 Zacks Investment Research
Evogene (EVGN) delivered earnings and revenue surprises of -42.86% and 46.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain
01:30pm, Wednesday, 18'th May 2022 GlobeNewswire Inc.
PALO ALTO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Na
Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer
04:05pm, Tuesday, 17'th May 2022
The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) investigational new drug application (IND) for Abivertinib (Fujovee) for Phase 2 MAVERICK study in metastatic castrate-resistant pr
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its license partner, China Oncology Focus Limited (“COF”), a subsidiary of
Kamada (KMDA) Reports Q1 Loss, Lags Revenue Estimates
12:25pm, Tuesday, 17'th May 2022 Zacks Investment Research
Kamada (KMDA) delivered earnings and revenue surprises of -233.33% and 13.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Albireo Pharma (ALBO) Reports Q1 Loss, Lags Revenue Estimates
09:15pm, Monday, 16'th May 2022 Zacks Investment Research
Albireo Pharma (ALBO) delivered earnings and revenue surprises of -8.42% and 12.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aravive (ARAV) Reports Q1 Loss, Tops Revenue Estimates
12:25pm, Thursday, 12'th May 2022 Zacks Investment Research
Aravive (ARAV) delivered earnings and revenue surprises of -16.98% and 2.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA™) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting
12:05am, Friday, 06'th May 2022 GlobeNewswire Inc.
PALO ALTO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Na
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its license and development partner, Sichuan Kelun-Biotech Biopharmaceutical
Why Sorrento Therapeutics Stock Shot 7% Higher Today
10:54pm, Monday, 02'nd May 2022 The Motley Fool
The company delivers some encouraging news about a COVID drug.
3 Penny Stocks to Watch During the Stock Market Crash
10:16pm, Monday, 02'nd May 2022 PennyStocks
Check these three penny stocks out as the stock market falls
The post 3 Penny Stocks to Watch During the Stock Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt
Why Sorrento Therapeutics Stock Shot 7% Higher Today
06:54pm, Monday, 02'nd May 2022
The company delivers some encouraging news about a COVID drug.
3 Penny Stocks to Watch During the Stock Market Crash
06:16pm, Monday, 02'nd May 2022
Check these three penny stocks out as the stock market falls The post 3 Penny Stocks to Watch During the Stock Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., to Present SP-102 (SEMDEXA™) Efficacy and Safety Data from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management at the 24th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) in Las Vegas, NV.
01:00pm, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
PALO ALTO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Expanding Its Direct Distribution Network to National And Regional Wholesalers And Pharmacies
04:46pm, Monday, 25'th Apr 2022 GlobeNewswire Inc.
PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “
